Value of miR-21 levels as potential biomarkers in the early diagnosis of hepatocellular carcinoma：a meta-analysis

References

• Ali, H., et al., 2017. Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma. Clinics and research in hepatology and gastroenterology, 41 (4), e51–e62.
   PubMed Web of Science ®Google Scholar
• Amr, K.S., et al., 2016. The potential role of miRNAs 21 and 199-a in early diagnosis of hepatocellular carcinoma. Gene, 575 (1), 66–70.
   PubMed Web of Science ®Google Scholar
• Bharali, D., et al., 2019. Expression analysis of MicroRNA-21 and MicroRNA-122 in hepatocellular carcinoma. Journal of clinical and experimental hepatology, 9 (3), 294–301.
   PubMed Web of Science ®Google Scholar
• Biselli, M., et al., 2015. A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. British journal of cancer, 112 (1), 69–76.
   PubMed Web of Science ®Google Scholar
• Cao, L.Q., et al., 2019. Exosomal miR-21 regulates the TETs/PTENp1/PTEN pathway to promote hepatocellular carcinoma growth. Molecular cancer, 18 (1), 148.
   PubMed Web of Science ®Google Scholar
• Chao, Y., and Zhou, D., 2019. lncRNA-D16366 Is a Potential Biomarker for Diagnosis and prognosis of Hepatocellular Carcinoma. Medical science monitor, 25, 6581–6586.
   PubMed Web of Science ®Google Scholar
• Chen, S., et al., 2018. Diagnostic Value of lncRNAs as Biomarker in Hepatocellular Carcinoma: An updated Meta-Analysis. Canadian journal of gastroenterology & hepatology, 2018, 8410195.
   PubMed Web of Science ®Google Scholar
• Chen, Z., et al., 2014. The changes of serum miR-21 expression level in patients with HCC before and after TACE and its clinical significance. J. Intervent. Radiol, 23, 406–410.
   Google Scholar
• Choi, B., and Lee, J., 2010. Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments: imaging diagnosis and staging of hepatocellular carcinoma. Journal of hepato-biliary-pancreatic sciences, 17 (4), 369–373.
   PubMed Web of Science ®Google Scholar
• Correa, G.C., et al., 2016. Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma. PLoS One, 11 (9), e0163699.
   PubMed Web of Science ®Google Scholar
• Feng, R.M., et al., 2019. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer communications (london, England), 39 (1), 22.
   PubMed Web of Science ®Google Scholar
• Fukushima, Y., et al., 2015. Clinical significance of microRNA-21 as a biomarker in each Dukes' stage of colorectal cancer. Oncology reports, 33 (2), 573–582.
   PubMed Web of Science ®Google Scholar
• Gebert, L.F., and MacRae, I.J., 2019. Regulation of microRNA function in animals. Nature reviews. Molecular cell biology, 20 (1), 21–37.
   PubMed Web of Science ®Google Scholar
• Gedawy, G., et al., 2017. Circulating MiRNA-21 and programed cell death (PDCD) 4 gene expression in hepatocellular carcinoma (HCC) in Egyptian patients. Egyptian journal of medical human genetics, 18 (2), 137–145.
   Google Scholar
• Ghosh, S., et al., 2020. The exosome encapsulated microRNAs as circulating diagnostic marker for hepatocellular carcinoma with low alpha-fetoprotein. International journal of cancer, 147 (10), 2934–2947.
   PubMed Web of Science ®Google Scholar
• Guo, X., et al., 2017. Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and correlated with distant metastasis. Oncotarget, 8 (27), 44050–44058.
   PubMedGoogle Scholar
• Hong, Y., et al., 2021. MiR-21-3p Promotes Hepatocellular Carcinoma Progression via SMAD7/YAP1 Regulation. Frontiers in oncology, 11, 642030.
   PubMed Web of Science ®Google Scholar
• Hu, L., et al., 2016. Long noncoding RNA GAS5 suppresses the migration and invasion of hepatocellular carcinoma cells via miR-21. Tumour biology : the journal of the international society for oncodevelopmental biology and medicine, 37 (2), 2691–2702.
   PubMedGoogle Scholar
• Hu, S., et al., 2015. MicroRNA-21 promotes cell proliferation in human hepatocellular carcinoma partly by targeting HEPN1. Tumor biology, 36 (7), 5467–5472.
   PubMedGoogle Scholar
• Huang, C.S., et al., 2015. Increased expression of miR-21 predicts poor prognosis in patients with hepatocellular carcinoma. Int J clin exp pathol, 8 (6), 7234–7238.
   PubMed Web of Science ®Google Scholar
• Jia, X., et al., 2014. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis. Archives of medical research, 45 (7), 580–588.
   PubMed Web of Science ®Google Scholar
• Jiang, Y., et al., 2019. The Diagnostic Value of MicroRNAs as a Biomarker for Hepatocellular Carcinoma: A Meta-Analysis. BioMed research international, 2019, 5179048.
   PubMed Web of Science ®Google Scholar
• Kamel, R.R., et al., 2016. Relation between microRNAs and Apoptosis in Hepatocellular Carcinoma. Open access macedonian journal of medical sciences, 4 (1), 31–37.
   PubMedGoogle Scholar
• Karakas, M., et al., 2017. Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease results from the large Athero Gene study. European heart journal, 38 (7), 516–523.
   PubMed Web of Science ®Google Scholar
• Kishimoto, T., et al., 2013. Plasma miR-21 is a novel diagnostic biomarker for biliary tract cancer. Cancer science, 104 (12), 1626–1631.
   PubMed Web of Science ®Google Scholar
• Kurashige, J., et al., 2012. Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. Journal of surgical oncology, 106 (2), 188–192.
   PubMed Web of Science ®Google Scholar
• Lai, C.Y., et al., 2021. MicroRNA-21 plays multiple oncometabolic roles in the process of NAFLD-related hepatocellular carcinoma via PI3K/AKT, TGF-β, and STAT3 signaling. Cancers, 13 (5), 940.
   PubMed Web of Science ®Google Scholar
• Lee, E., et al., 2017. High expression of lncRNA-ATB and miR-21 as a biomarker in human hepatocellular carcinoma. Cancer research, 77.
   Web of Science ®Google Scholar
• Li, J., 2014. Prognostic and clinicopathological significance of glypican-3 over expression in hepatocellular carcinoma: a meta-analysis. World journal of gastroenterology, 20 (20), 6336–6344.
   PubMed Web of Science ®Google Scholar
• Liao, Q., et al., 2015. Potential role of circulating microRNA-21 for hepatocellular carcinoma diagnosis: a meta-analysis. PLoS One, 10 (6), e0130677.
   PubMed Web of Science ®Google Scholar
• Lin, L., et al., 2018. Empirical comparison of publication bias tests in meta-analysis. Journal of general internal medicine, 33 (8), 1260–1267.
   PubMed Web of Science ®Google Scholar
• Liu, A.M., et al., 2012. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ open, 2 (2), e000825.
   PubMed Web of Science ®Google Scholar
• Lu, J., et al., 2020. Hypomethylation causes MIR21 overexpression in tumors. Molecular therapy oncolytics, 18, 47–57.
   PubMed Web of Science ®Google Scholar
• Lv, Z., et al., 2018. Cluster of specified microRNAs in tissues and serum as biomarkers for early diagnosis of hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 11 (2), 990–997.
   PubMed Web of Science ®Google Scholar
• Marrero, J.A., et al., 2005. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. Journal of hepatology, 43 (6), 1007–1012.
   PubMed Web of Science ®Google Scholar
• Marrero, J.A., et al., 2009. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology, 137 (1), 110–118.
   PubMed Web of Science ®Google Scholar
• Marrero, J.A., and Lok, A.S., 2004. Newer markers for hepatocellular carcinoma. Gastroenterology, 127 (5 Suppl 1), S113–S119.
   PubMed Web of Science ®Google Scholar
• Qu, J., et al., 2019. MicroRNA-21 as a diagnostic marker for hepatocellular carcinoma: A systematic review and meta-analysis. Pakistan journal of medical sciences, 35 (5), 1466–1471.
   PubMed Web of Science ®Google Scholar
• Ren, J., et al., 2017. The diagnostic and prognostic values of microRNA-21 in patients with gastric cancer: a meta-analysis. European review for medical and pharmacological sciences, 21 (1), 120–130.
   PubMed Web of Science ®Google Scholar
• Ronot, M., et al., 2011. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology (baltimore, Md.), 53 (4), 1182–1191.
   PubMed Web of Science ®Google Scholar
• Shan, L., et al., 2015. Diagnostic value of circulating miR-21 for colorectal cancer: a meta-analysis. Cancer biomarkers : section A of disease markers, 15 (1), 47–56.
   PubMed Web of Science ®Google Scholar
• Shang, S., et al., 2012. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology (baltimore, Md.), 55 (2), 483–490.
   PubMed Web of Science ®Google Scholar
• Shao, Y.Y., et al., 2010. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer, 116 (19), 4590–4596.
   PubMed Web of Science ®Google Scholar
• Sturgeon, C.M., et al.,; National Academy of Clinical Biochemistry. 2010. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clinical chemistry, 56 (6), e1–e48.
   PubMed Web of Science ®Google Scholar
• Suehiro, T., et al., 2017. Significance of serum exosomal miR-122 and miR-21 as a predictive biomarker in hepatocellular carcinoma patients who underwent transarterial chemoembolization. Journal of hepatology, 66 (1), S624–S624.
   Web of Science ®Google Scholar
• Tian, X.P., et al., 2019. Acidic microenvironment up-regulates exosomal mir-21 and mir-10b in early-stage hepatocellular carcinoma to promote cancer cell proliferation and metastasis. Theranostics, 9 (7), 1965–1979.
   PubMed Web of Science ®Google Scholar
• Tomimaru, Y., et al., 2012. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. Journal of hepatology, 56 (1), 167–175.
   PubMed Web of Science ®Google Scholar
• Torre, L.A., et al., 2015. Global cancer statistics, 2012. CA: a cancer journal for clinicians, 65 (2), 87–108.
   PubMed Web of Science ®Google Scholar
• Venazzi, A., et al., 2018. Validity of the QUADAS-2 in assessing risk of bias in alzheimer's disease diagnostic accuracy studies. Frontiers in psychiatry, 9, 221.
   PubMed Web of Science ®Google Scholar
• Wang, J., et al., 2019. miR-21 promotes cell migration and invasion of hepatocellular carcinoma by targeting KLF5. Oncology letters, 17 (2), 2221–2227.
   PubMed Web of Science ®Google Scholar
• Wang, M., et al., 2018. CircRNAs as biomarkers of cancer: a meta-analysis. BMC cancer, 18 (1), 303.
   PubMed Web of Science ®Google Scholar
• Wang, P., et al., 2017. Application of microdrop digital PCR in detection of serum miR-21 and miR-4429 in the diagnosis of liver cancer. Zhe jiang medicine, 39 (3), 923–932.
   Google Scholar
• Wang, W.Y., et al., 2014. miR-21 expression predicts prognosis in hepatocellular carcinoma. Clinics and research in hepatology and gastroenterology, 38 (6), 715–719.
   PubMed Web of Science ®Google Scholar
• Wang, X., et al., 2015. Significance of serum microRNA-21 in diagnosis of hepatocellular carcinoma (HCC): clinical analyses of patients and an HCC rat model. International Journal of Clinical and Experimental Pathology, 8 (2), 1466–1478.
   PubMed Web of Science ®Google Scholar
• Wang, Y.C., et al., 2014. Golgi protein 73, not glypican-3, may be a tumor marker complementary to α-fetoprotein for hepatocellular carcinoma diagnosis. Journal of gastroenterology and hepatology, 29 (3), 597–602.
   PubMed Web of Science ®Google Scholar
• Wang, Z., et al., 2015. MiR-21 promoted proliferation and migration in hepatocellular carcinoma through negative regulation of Navigator-3. Biochemical and biophysical research communications, 464 (4), 1228–1234.
   PubMed Web of Science ®Google Scholar
• Wong, C.H., et al., 2006. The molecular diagnosis of hepatitis B virus-associated hepatocellular carcinoma. Critical reviews in clinical laboratory sciences, 43 (1), 69–101.
   PubMed Web of Science ®Google Scholar
• Wu, C., et al., 2020. Micro-RNA-21 rs1292037 A > G polymorphism can predict hepatocellular carcinoma prognosis (HCC), and plays a key role in cell proliferation and ischemia-reperfusion injury (IRI) in HCC cell model of IRI. Saudi medical journal, 41 (4), 383–392.
   PubMed Web of Science ®Google Scholar
• Xu, F., et al., 2015. The accuracy of circulating microRNA-21 in the diagnosis of colorectal cancer: a systematic review and meta-analysis. Colorectal disease, 17 (5), O100–O107.
   PubMed Web of Science ®Google Scholar
• Xu, J., et al., 2011. Circulating MicroRNAs, miR-21, miR-122, and miR-223, in Patients with Hepatocellular Carcinoma or Chronic Hepatitis. Molecular carcinogenesis, 50 (2), 136–142.
   PubMed Web of Science ®Google Scholar
• Yoon, J.S., et al., 2018. Clinical significance of microRNA-21 expression in disease progression of patients with hepatocellular carcinoma. Biomarkers in medicine, 12 (10), 1105–1114.
   PubMed Web of Science ®Google Scholar
• Yu, Z., and Cheng, A.S., 2013. Epigenetic deregulation of microRNAs: new opportunities to target oncogenic signaling pathways in hepatocellular carcinoma. Current pharmaceutical design, 19 (7), 1192–1200.
   PubMed Web of Science ®Google Scholar
• Zeng, Z., et al., 2013. Potential role of microRNA-21 in the diagnosis of gastric cancer: a meta-analysis. PLoS One, 8 (9), e73278.
   PubMed Web of Science ®Google Scholar
• Zhang, N., et al., 2019. Circulating miR-130b- and miR-21-based diagnostic markers and therapeutic targets for hepatocellular carcinoma. Molecular genetics & genomic medicine, 7 (12), e1012.
   PubMed Web of Science ®Google Scholar
• Zhu, Q., et al., 2012. miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular atocellular carcinoma. Oncology reports, 27 (5), 1660–1668.
   PubMed Web of Science ®Google Scholar
• Zhuang, C., et al., 2016. Serum miR-21, miR-26a and miR-101 as potential biomarkers of hepatocellular carcinoma. Clinics and research in hepatology and gastroenterology, 40 (4), 386–396.
   PubMed Web of Science ®Google Scholar